RecruitingNCT07250347

AI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CT

Langue and Imaging-integrated Foundation Model for Gastric Cancer Detection and Staging Via Contrast-Enhanced CT: a Multicenter Study


Sponsor

The First Affiliated Hospital with Nanjing Medical University

Enrollment

8,000 participants

Start Date

Aug 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Accurate preoperative assessment of gastric cancer stage guides eligibility for endoscopic resection, extent of gastrectomy and lymphadenectomy, selection for neoadjuvant therapy, and use of staging laparoscopy. Contrast-enhanced CT (CECT) is guideline-endorsed for initial staging, yet performance varies across institutions and readers. This study will evaluate an artificial-intelligence (AI) system that analyzes routine CECT to detect gastric cancer and assign four-class T stage (T1-T4) and N stage (N0-N3) .


Eligibility

Min Age: 18 YearsMax Age: 85 Years

Inclusion Criteria4

  • pathologically confirmed gastric cancer;
  • preoperative contrast-enhanced CT performed;
  • no evidence of distant metastasis on baseline staging;
  • curative-intent management with complete postoperative histopathology.

Exclusion Criteria2

  • prior treatment before surgery;
  • non-diagnostic or poor-quality CT precluding evaluation.

Interventions

DIAGNOSTIC_TESTCT scan

preoperative contrast-enhanced CT


Locations(1)

The First Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07250347


Related Trials